NCT04589845
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ROS, NTRK, ALK, TMB-H, Akt, HER2, PI3K, MDM2
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Tyrosine-Kinase Inhibitor, Serine Threonine Kinase Inhibitor, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT04589845